Cas no 119309-36-3 (4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)-)

The compound (2R,3R)-2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-4H-1-benzopyran-4-one is a chiral flavonoid derivative with notable structural and functional properties. Its stereospecific (2R,3R) configuration ensures precise molecular interactions, making it valuable for research in enantioselective synthesis and pharmacological studies. The presence of hydroxyl and methoxy substituents enhances its potential as an intermediate in the development of bioactive molecules, particularly in antioxidant and anti-inflammatory applications. Its rigid benzopyranone core contributes to stability, while the phenyl group at the 2-position offers opportunities for further functionalization. This compound is suitable for investigations in medicinal chemistry and natural product synthesis due to its defined stereochemistry and reactive sites.
4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)- structure
119309-36-3 structure
Product Name:4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)-
CAS No:119309-36-3
MF:C16H14O5
MW:286.279365062714
CID:217859
PubChem ID:147459
Update Time:2025-05-20

4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)- Chemical and Physical Properties

Names and Identifiers

    • 4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)-
    • Pinobanksin 5-methyl ether
    • 5-O-Methylpinobanksin
    • 4H-1-Benzopyran-4-one, 2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)-
    • (2R,3R)-3,7-dihydroxy-5-methoxy-2-phenyl-2,3-dihydrochromen-4-one
    • (2R,3R)-3,7-Dihydroxy-5-methoxy-2-phenylchroman-4-one
    • F94019
    • 87620-04-0
    • DTXSID40922934
    • (2R,3R)-3,7-dihydroxy-5-methoxy-2-phenyl-3,4-dihydro-2H-1-benzopyran-4-one
    • CHEMBL1096213
    • AKOS030552798
    • 3,7-Dihydroxy-5-methoxy-2-phenyl-2,3-dihydro-4H-1-benzopyran-4-one
    • CS-0158964
    • 119309-36-3
    • Pinobanksin-5-methylether
    • HY-N9203
    • Pinobanksin_5-methylether
    • DA-76896
    • Inchi： 1S/C16H14O5/c1-20-11-7-10(17)8-12-13(11)14(18)15(19)16(21-12)9-5-3-2-4-6-9/h2-8,15-17,19H,1H3/t15-,16+/m0/s1
    • InChI Key： NIMIDMFTGGTHOH-JKSUJKDBSA-N
    • SMILES： O1C2C=C(C=C(C=2C([C@@H]([C@H]1C1C=CC=CC=1)O)=O)OC)O

Computed Properties

  • Exact Mass: 286.084
  • Monoisotopic Mass: 286.084
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 5
  • Heavy Atom Count: 21
  • Rotatable Bond Count: 2
  • Complexity: 379
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 2
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 2
  • Topological Polar Surface Area: 76?2

Experimental Properties

  • Color/Form: Powder
  • Density: 1.38
  • Boiling Point: 549.8°Cat760mmHg
  • Flash Point: 209.9°C
  • Refractive Index: 1.64
  • Vapor Pressure: 0.0±1.6 mmHg at 25°C

4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)- Security Information

4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)- Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
P91550-5 mg
4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)-
 119309-36-3
5mg
 ￥4640.0 2021-09-08
TargetMol Chemicals
TN4790-1 ml * 10 mm
Pinobanksin 5-methyl ether
 119309-36-3
1 ml * 10 mm
 ￥ 12180 2024-07-19
TargetMol Chemicals
TN4790-5 mg
Pinobanksin 5-methyl ether
 119309-36-3 98%
5mg
 ￥ 10,150 2023-07-10
TargetMol Chemicals
TN4790-1 mL * 10 mM (in DMSO)
Pinobanksin 5-methyl ether
 119309-36-3 98%
1 mL * 10 mM (in DMSO)
 ￥ 12180 2023-09-15
TargetMol Chemicals
TN4790-5mg
Pinobanksin 5-methyl ether
 119309-36-3
5mg
 ￥ 10150 2024-07-19

4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)- Related Literature

Related Categories

Additional information on 4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)-

4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)-

4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)- is a complex organic compound with the CAS registry number 119309-36-3. This compound belongs to the class of benzopyrans, which are aromatic heterocyclic compounds with a benzene ring fused to a gamma-pyrone ring. The structure of this compound is characterized by a benzopyran skeleton with hydroxyl groups at positions 3 and 7, a methoxy group at position 5, and a phenyl group attached at position 2. The stereochemistry of the molecule is specified as (2R,3R), indicating the configuration of the chiral centers at positions 2 and 3.

The synthesis of 4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)- involves multi-step organic reactions. Recent advancements in synthetic methodologies have enabled the construction of such complex molecules with high stereoselectivity. One notable approach involves the use of enantioselective catalysis to achieve the desired stereochemistry at positions 2 and 3. Researchers have also explored the use of microwave-assisted synthesis to accelerate reaction times while maintaining product purity.

4H-1-Benzopyran derivatives have been extensively studied for their potential biological activities. Recent studies have highlighted the antioxidant properties of this compound, which are attributed to its ability to scavenge free radicals and inhibit lipid peroxidation. In vitro assays have demonstrated that 4H-benzopyran derivatives can effectively reduce oxidative stress in human cells, making them promising candidates for applications in antioxidant therapies.

In addition to its antioxidant activity, 4H-benzopyran derivatives have shown potential in anti-inflammatory and anticancer research. A study published in *Journal of Medicinal Chemistry* revealed that 4H-benzopyran derivatives can inhibit the activity of cyclooxygenase enzymes, which are key players in inflammation. Furthermore, preclinical studies have indicated that these compounds may exhibit cytotoxic effects against various cancer cell lines.

The pharmacokinetic properties of 4H-benzopyran derivatives are another area of active research. Studies using animal models have shown that these compounds exhibit good bioavailability when administered orally or intravenously. However, further research is needed to optimize their pharmacokinetic profiles for therapeutic applications.

From an environmental perspective, the biodegradability and eco-toxicity of 4H-benzopyran derivatives have also been investigated. Results from eco-toxicological studies suggest that these compounds are not highly toxic to aquatic organisms under normal exposure conditions. Nonetheless, their long-term effects on ecosystems remain an area requiring further investigation.

In conclusion,4H-benzopyran derivatives, including 4H-benzopyranone, continue to be a focal point in chemical research due to their diverse biological activities and potential therapeutic applications. As researchers delve deeper into their synthesis and biological properties,CAS No: 119309 - 36 - 3 will likely play an increasingly important role in drug discovery and development.

119309-36-3 (4H-1-Benzopyran-4-one,2,3-dihydro-3,7-dihydroxy-5-methoxy-2-phenyl-, (2R,3R)-) Related Products

Recommended suppliers
Suzhou Genelee Bio-Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Suzhou Genelee Bio-Technology Co., Ltd.
Hangzhou Cedareal Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Hangzhou Cedareal Technology Co., Ltd.
上海帛亦醫(yī)藥科技有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hubei Cuiyuan Biotechnology Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hubei Cuiyuan Biotechnology Co.,Ltd
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hangzhou TSurgeX Pharmaceutical Technology Co., Ltd.